Results 101 to 110 of about 1,785 (194)

LC-MS/MS quantification of omadacycline in human plasma for therapeutic drug monitoring: method development and clinical application

Scientific Reports
Omadacycline, a third-generation tetracycline antibiotic, exhibits time-dependent pharmacokinetics. The ratio of the 24-hour area under the concentration-time curve to minimum inhibitory concentration (AUC0−24/MIC) serves as the primary pharmacokinetic ...
Yueyuan Wang, Zhipeng Diao, Yuchen Qu, Kai Fan, Chen Feng, Bo Lv, Yunli Yu, Zhou Geng   +7 more
doaj   +1 more source

Omadacycline successfully treated severe Legionella pneumonia after moxifloxacin treatment failure: Case series

Frontiers in Pharmacology
Legionella is a significant pathogen responsible for community-acquired pneumonia and, less commonly, for hospital-acquired pneumonia. Legionella pneumophila, the most prevalent species within the Legionella genus, accounts for 80%–90% of human ...
Biyun Li, Laiyu Liu, Fei Li, Chunmei He, Yuan Chen, Xiaodong Tian, Zhenyu Liu, Weizhen Zhang   +7 more
doaj   +1 more source

In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis

, 2017
The in vitro activity and in vivo efficacy of omadacycline (OMC) were evaluated against the causative pathogens of anthrax and plague, Bacillus anthracis and Yersinia ...
Judith Steenbergen, Stephanie A. Halasohoris, Lynda L. Miller, S. Ken Tanaka, Jeremy R. Hershfield   +4 more
core   +1 more source

Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines

, 2019
Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections.
Emília Sousa, Fernando Durães
core   +1 more source

In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model

, 2017
Omadacycline is a novel aminomethylcycline antibiotic in clinical development for community-acquired bacterial pneumonia (CABP). We used a neutropenic murine pneumonia infection model to characterize the in vivo pharmacodynamic ...
Karen Marchillo, David R. Andes, Miao Zhao, Jamie VanHecker, Alexander J. Lepak   +4 more
core   +1 more source

Omadacycline

Reactions Weekly
  +5 more sources

Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus Aureus by pharmacokinetic/pharmacodynamic analysis

Omadacycline is an FDA-approved agent for community-acquired bacterial pneumonia (CABP). The purpose of this study is to evaluate the effectiveness of omadacycline for treating CABP patients infected with Staphylococcus aureus, including Methicillin ...
Junfeng Zhu (2052082), Haiying Ding (9333865), Jiaqi Wang (369548), Dihong Yang (18426494), Luo Fang (10183704), Like Zhong (426317), Gaoqi Xu (9333874), Chaoneng He (14266258), Xin Liu (43569), Yuqing Mei (9033053)   +9 more
core   +1 more source

Efficacy and Safety of Omadacycline in Patients with Mycoplasma Pneumoniae Harboring the 23S rRNA A2063G Mutation

Infection and Drug Resistance
Min Chen,* Wei An,* Shasha Fang,* Mingwei Zhang Department of Pharmacy, The Third People’s Hospital of Hubei Province, Wuhan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Mingwei
Chen M, An W, Fang S, Zhang M
doaj  

Omadacycline use in a traveler with severe Legionella pneumonia

Travel Medicine and Infectious Disease, 2023
Jianfeng Wang, Jiahuan Tong, Ying Wang, Yan Chen   +3 more
openaire   +3 more sources

Omadacycline Monotherapy in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus: Results From a Phase 2, Double-blind, Randomized, Placebo-controlled Study. [PDF]

Clin Infect Dis
Winthrop KL, Flume PA, Khare R, Sriaroon C, Sirbu A, Manley A, Das AF, Chitra S, Deck DH, Serio AW, Anastasiou DM, Villano S.   +11 more
europepmc   +1 more source